Genotyping Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Sequencing is the fastest growing sector, North America is the largest market

The Global Genotyping Market is projected for substantial growth, expanding from USD 16.72 Billion in 2025 to USD 27.86 Billion by 2031, at an 8.88% CAGR. This market expansion is primarily driven by the increasing prevalence of chronic genetic diseases and the crucial role of genomic analysis in both pharmacogenomics and the development of targeted therapies.

The growing reliance on genetic insights for disease management is evidenced by projections such as the American Cancer Society's estimate of approximately 2,041,910 new cancer cases in the United States alone in 2025, highlighting a critical global demand for precision oncology and genetic profiling technologies. Despite this strong growth, the market faces significant challenges, particularly concerning data privacy and security. The necessity to adhere to stringent and often varied regional regulatory standards for handling vast amounts of sensitive genetic information creates considerable operational complexities and liability risks for diagnostic providers and research institutions, thereby impeding the seamless exchange of genomic data vital for large-scale research and broader clinical implementation of genotyping services.

Market Drivers

The genotyping market is primarily propelled by two key factors: significant cost reductions in DNA sequencing and genomic analysis, and the expanding applications of precision medicine and pharmacogenomics. Substantial decreases in sequencing costs, driven by maturing high-throughput technologies, have democratized access to genetic data, enabling laboratories to process vast sample volumes that were previously cost-prohibitive.

This economic shift fuels the scalability of population-health studies and commercial diagnostics, as demonstrated by Illumina's Q1 2025 report showing over 30 percent year-over-year increase in sequencing gigabase output and UK Biobank's release of comprehensive metabolomics data for 500,000 participants. Concurrently, the growth of precision medicine and pharmacogenomics is fundamentally reshaping therapeutic development; pharmaceutical companies and clinicians increasingly use genotypic data to identify biomarkers, predicting drug efficacy and toxicity to optimize treatment outcomes. This transition to targeted regimens is heavily supported by regulatory trends, with the Personalized Medicine Coalition reporting that 38 percent of new FDA-approved therapeutic molecular entities in 2024 were personalized medicines, underscoring the central role of genetic profiling in modern drug discovery and approval.

Market Challenges

Data privacy and security represent a critical challenge significantly hindering the Global Genotyping Market's growth. The industry's reliance on aggregating massive datasets of sensitive genetic profiles for pharmacogenomics and precision medicine makes it highly vulnerable to cyber threats. The imperative to comply with rigorous and often fragmented regulatory standards across various jurisdictions creates substantial operational bottlenecks, diverting resources from innovation and complicating the cross-border sharing of genomic data essential for biomarker validation and large-scale research. The inherent liability risks associated with maintaining these data pools prompt stakeholders to restrict access, directly stalling clinical implementation. The severity of this vulnerability is illustrated by the American Hospital Association's report that cyberattacks and data breaches within the healthcare sector impacted a record 259 million individuals in the United States in 2024, leading to eroded patient trust and the establishment of restrictive data silos that impede seamless information exchange vital for market expansion.

Market Trends

Two pivotal trends are shaping the genotyping market: the integration of Artificial Intelligence (AI) for genotypic data interpretation and the increasing application in agricultural biotechnology and animal breeding. AI integration is addressing analytical bottlenecks caused by exponential genomic dataset growth, with the market shifting towards AI-driven platforms that automate complex variant classification and clinical reporting, moving beyond manual bioinformatics.

This demand for computational efficiency is evident in Tempus AI Inc.'s Q3 2024 report, showing a 64.4 percent year-over-year acceleration in its AI-enabled data platform's revenue to $64.5 million, highlighting the industry's growing reliance on intelligent algorithms for actionable precision medicine insights. Simultaneously, genotyping's expanded application in agricultural biotechnology and animal breeding broadens its scope beyond human healthcare, utilizing genomic selection tools to enhance food security and livestock productivity. Agribusinesses are extensively adopting these tools to identify desirable traits like disease resistance and feed efficiency, optimizing breeding programs and reducing operational risks, a resilience demonstrated by Neogen Corporation's Annual Report 2024, which noted an 8 percent increase in its Genomics Services revenue, underscoring genotyping's critical role in modernizing agricultural supply chains and ensuring sustainable production standards.

Key Market Players

• Thermo Fisher Scientific Inc.
• Illumina Inc.
• QIAGEN N.V.
• F Hoffmann-La Roche AG
• Danaher Corporation
• Agilent Technologies, Inc.
• Eurofins Scientific Inc.
• General Electric Compnay
• Bio-Rad Laboratories Inc.
• Standard BioTools Inc.

Report Scope

In this report, the Global Genotyping Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Genotyping Market, by Product:

• Instruments
• Reagents & Kits
• Software
• Services

Genotyping Market, by Technology:

• PCR
• Capillary Electrophoresis
• Microarrays
• Sequencing
• Mass Spectrometry
• Others

Genotyping Market, by Application:

• Pharmacogenomics
• Diagnostics and Personalized Medicine
• Agricultural Biotechnology
• Animal Genetics
• Others

Genotyping Market, by End Use:

• Pharmaceutical and Biopharmaceutical Companies
• Diagnostics and Research Laboratories
• Academic Institutes
• Others

Genotyping Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Genotyping Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.